TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02280070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Endoscopy for lower digestive tract

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Endoscopy for lower digestive tract

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBs antibody and HBc antibody
Description: Check according to hepatitis B guideline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBs antibody and HBc antibody
Description: Check according to hepatitis B guideline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP (130mg/m2)
Description: L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-OHP (85 mg/m2)
Description: L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV
Description: l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
Study: NCT01162070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free strategy
Description: Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized strategy
Description: Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
Study: NCT02030418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leadless Pacemaker
Description: Patients will undergo an attempted leadless pacemaker implant
Study: NCT01868503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03152149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate & vilanterol
Description: Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
Study: NCT02900365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early cataract surgery & IOL implantation
Description: first week cataract extraction and IOL implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: late cataract surgery & IOL implantation
Description: first month cataract extraction and IOL implantation.
Study: NCT03939572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accurate step count feedback
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deflated step count feedback
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inflated step count feedback
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accurate feedback + mindset intervention
Description: After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets.
Study: NCT01636206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year
Study: NCT01428349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
Study: NCT01624636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316
Study: NCT03210402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elevated night pacing on
Description: Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Elevated night pacing off
Description: Device will be programmed to normal lower rates
Study: NCT04716933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching lenvatinib
Description: Oral capsule once daily
Study: NCT00362843

Intervention type: DRUG
Intervention: [15-O]water
Study: NCT03370406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Intralesional injections of 50mg/ml over a 3 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Intralesional injections of 50mg/ml over a 3 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Topical application of 5% cream over a 3 week period.
Study: NCT01740557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGFR-transduced Autologous T Lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03371329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: bone marrow derived cultured MSC (mesenchymal stem cell)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: bone marrow derived cultured MSC (mesenchymal stem cell)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: bone marrow derived cultured MSC (mesenchymal stem cell)
Study: NCT00709306

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV-Detect Photos
Description: UV-Detect Photos

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV-Detect Photos
Description: UV-Detect Photos

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Education
Study: NCT02283255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Supervised aerobic and light muscle resistance exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training with POWERbreathe device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Exercise Training
Description: Usual care
Study: NCT00823979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061 Dose 1
Description: UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061 Dose 2
Description: UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etravirine
Description: Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
Study: NCT03771885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated Tablet
Study: NCT02050594

Intervention type: DRUG
Intervention: Ipilimumab
Study: NCT03684733

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Clinical MRI breast screening examination

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Clinical MRI breast screening examination

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Clinical MRI breast screening examination

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Clinical MRI breast screening examination
Study: NCT03459183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrasound (85 dB; 6Hz) source
Description: the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (10dB below hearing threshold; 22.4 kHz) source
Description: the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Infrasound dummy source
Description: the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound dummy source
Description: the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
Study: NCT00639613

Intervention type: PROCEDURE
Intervention: Double-balloon enteroscopy
Description: Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.

Intervention type: PROCEDURE
Intervention: Double-balloon enteroscopy
Description: Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.

Intervention type: OTHER
Intervention: Standard meal test
Description: Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations.

Intervention type: OTHER
Intervention: Standard meal test
Description: Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations.
Study: NCT02431143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Study: NCT04083651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
Study: NCT01928004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional reline
Description: conventional reline of the existing mandibular complete denture
Study: NCT00303849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study: NCT02842658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A high-intensity interval exercise group
Description: To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
Study: NCT02636829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QALCIMUM questionnaire
Description: All patients will fill out the QALCIMUM questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QALCIMUM questionnaire
Description: All patients will fill out the QALCIMUM questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of calcium intake by a dietician interview
Description: All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL \*.~\* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of calcium intake by a dietician interview
Description: All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL \*.~\* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital.
Study: NCT01388452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care HIV RNA PCR
Description: The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
Study: NCT00075686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000mg/m2 IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000mg/m2 IV over 30 minutes
Study: NCT01684059

Intervention type: DIETARY_SUPPLEMENT
Intervention: zinc sulfate
Description: every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
Study: NCT03011060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemotherapy
Description: A preoperative chemotherapy based on anthracyclines and taxanes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemotherapy
Description: A preoperative chemotherapy based on anthracyclines and taxanes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
Study: NCT02371928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular exercise program
Description: Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard home exercise program
Description: Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions.
Study: NCT03091257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Administered Orally BID
Study: NCT02842658

Intervention type: OTHER
Group type: OTHER
Intervention: An Attention-Control Group
Description: Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
Study: NCT04461756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPP001
Description: inhalation (vape)
Study: NCT02824432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-085
Description: TAK-085 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-085
Description: TAK-085 capsules